A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

985

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Primary Progressive

Interventions

DRUG: Fenebrutinib
DRUG: Ocrelizumab
DRUG: Placebo matched to ocrelizumab
DRUG: Placebo matched to fenebrutinib

Sponsor

Hoffmann-La Roche